CD274 and neoplasm: In the context of immunotherapy for NSCLC, several factors have been reported for monitoring efficacy and predicting clinical prognosis; these factors include multiple mechanisms, including dynamic immune TME profiles [22], PD-L1 expression [23], radiomics [24], tumor mutation burden, and immunoinflammatory indicators [25, 26].